The Rise and Maturation of European Life Sciences and Healthcare Real Estate

► European Life Sciences and Healthcare Real Estate

The global population exceeded 8 billion in November 2022 and is projected to expand by 21% by 2050 and 36% by 2100, accelerating long-term demand for healthcare infrastructure. As of January 2026, the EU population stood at 452 million. 

Demographic trends across Europe indicate that the proportion of citizens aged over 65 will rise from 19.1% to 28.1% of the total population by 2050, while the cohort aged 80 and over is projected to triple, reaching 15.3% by 2050. Consequently, the EU old-age dependency ratio increased to 34.4% in 2025 and is forecasted to hit 50.4% by 2050. 

Structural expansion across the sector is driven by demographic change, diseases of civilisation, escalating healthcare expenditure, technological change, urbanisation, the war for talent, sustainability imperatives, and the legacy of COVID-19.

Global pharmaceutical research and development expenditure reached EUR 236bn in 2022, marking an 86.1% increase compared to 2010. Over the same period, European pharmaceutical R&D spending expanded by 53.2% to reach EUR 42.7bn, and it is projected to hit approximately EUR 283bn by 2028. 

Europe hosts the headquarters of four of the world's 10 largest pharmaceutical companies by R&D spend, which collectively deployed USD 48bn in R&D during 2025. 

Across the top 10 global pharmaceutical firms, total R&D deployment reached USD 125bn in 2025, representing an average R&D intensity of 20.1% relative to corporate revenue. Venture capital funding into European life sciences rebounded to EUR 14.6bn in 2025, achieving a 7% annual growth rate and approaching pandemic-era record highs. 

Artificial intelligence-driven drug discovery captured 20% of European venture capital in 2025, driving specialised demand for tech-ready dry laboratories alongside traditional wet laboratory space. However, Europe's share of global Phase I-III clinical trial starts dropped from 35% in 2009 to 21% in 2024, as China's share climbed to 30%.

European life sciences real estate assets remain highly competitive on a global scale, costing approximately 40% less to acquire than their US counterparts, while corporate biotech operational costs in Europe run about 50% lower than in the US. 

Life sciences property accounted for 0.5% of total European commercial property investment activity in 2020, down from 1.4% in 2015. Between late 2020 and late 2022, transaction activity underwent a structural shift away from fund manager dominance toward deals led by project developers and investment managers. 

Regional cluster dynamics remain critical to operational performance; life sciences firms located within established clusters demonstrate 10% to 40% higher productivity than isolated competitors due to knowledge transfer, interdisciplinary collaboration, and operational synergies. 

Outside of owner-occupied developments, few individual European markets generate more than 15,000 sq m in annual laboratory space take-up.

Total European nursing home investment volume reached EUR 16.1bn in 2025, heavily propelled by transaction activity in the UK. Excluding the UK, Continental European investment volumes recorded a recovery to almost double 2024 levels, reflecting a broader regional recovery. 

Private operators currently manage approximately 40% of European nursing home beds, though private market share reaches 75% to 85% in core markets such as Italy, Ireland, and the UK. 

European healthcare prime yields broadly stabilised in 2025 around 5.00% across mature markets, while prime yields in Southern Europe hovered near 5.75%. 

Corporate and platform consolidation accelerated across the continent, marked by major corporate mergers, strategic asset disposals, and the establishment of dedicated institutional real estate platforms across core markets. 

Sustainability metrics show that European healthcare real estate achieved an average 7.48% reduction in energy consumption in 2023, although primary energy consumption averaged 292 kWhPE/sq m and carbon emissions averaged 35.8 kgCO2eq/sq m.

Across 154 documented European transactions, 81% of life sciences leases carry a duration of 10 years or longer, yielding an average contractual lease length of 12.8 years. Lease terms cluster heavily around round figures, with 10-, 12-, 15-, 20-, and 25-year terms accounting for 73% of all agreements. 

Approximately 80% of leases extending to 20 years or longer represent single-tenant commitments, typically structured through sale-and-leaseback transactions or build-to-suit developments. 

Contractual terms scale directly with facility footprint, averaging 10.3 years for properties under 2,300 sq m, 12.2 years for mid-sized facilities between 2,400 sq m and 6,400 sq m, and 14.4 years for large assets exceeding 6,400 sq m. 

By asset typology, point-of-care facilities command the longest average duration at 14.7 years, followed by production (13.1 years), distribution (12.1 years), R&D (12.0 years), and mixed-use assets (11.3 years). 

This contrasts sharply with mainstream European commercial leases structured around 3- to 7-year blocks.

► United Kingdom

The UK consolidated its position as Europe's premier life sciences destination, with venture capital funding into UK life sciences reaching around GBP 2 billion in Q2 2026, marking a 135% quarter-on-quarter increase and standing 102% above the five-year quarterly average. 

Late-stage funding rounds dominated capital deployment at GBP 1,834.3 million (91% of total), while early-stage funding recorded GBP 106.4 million (5%), and seed investment reached GBP 64.4 million (3%).

London captured GBP 1,710.1 million (85% of national VC funding), driven by a major artificial intelligence venture securing a GBP 1,550.7 million late-stage deal. By mid-June 2026, London life sciences VC investment had reached GBP 2.2bn, representing a 50% increase over mid-2025 levels. 

Cambridge firms secured GBP 209.9 million (10.5%), Oxford firms raised GBP 28.6 million (1.4%), and the rest of the UK accounted for GBP 56.6 million (2.8%). 

Macroeconomic and trade policy has further reinforced sector tailwinds. Under a UK-US trade arrangement, UK pharmaceutical exports are exempt from US tariffs until 19 January 2029, in exchange for the UK raising national medicine spending from 0.3% of GDP in 2026 to 0.6% by 2036, which will inject up to GBP 14bn into healthcare funding. 

Although UK laboratory space demand surged to record highs in Q3 2026, with rolling four-quarter take-up surpassing 1.2 million sq ft, quarterly Golden Triangle occupier take-up in Q2 2026 stood at 175,000 sq ft - representing a 57% decline from Q1 2026 and sitting 8% below the five-year average.

London led Q2 leasing with 98,300 sq ft across five transactions (56% of Golden Triangle take-up), highlighted by a confidential occupier taking all 85,500 sq ft at Jahn Court in the Regent Quarter. 

Supply completions over the last two years total 1.8 million sq ft across the Golden Triangle, pushing UK national lab vacancies to a record 14.3% and Golden Triangle vacancies above 25%.

High construction costs, elevated financing rates, and vacancy expansion have curtailed speculative starts, reducing under-construction space across the Golden Triangle to 2.9 million sq ft-its lowest level since Q1 2024-with 20% pre-let or under offer. 

The broader UK construction pipeline shrank 13% during 2026 to roughly 3 million sq ft, with under 130,000 sq ft breaking ground in 2026. Although 4.2 million sq ft holds planning consent for potential delivery by 2029, uncommitted completions due by late 2026 are expected to temporarily inflate vacancy rates before delivery slows in 2027.

Occupier requirements are shifting away from traditional office-laboratory divides toward multi-functional spaces integrating wet and dry labs, cleanrooms, pilot plants, advanced manufacturing, and high-performance computing. 

Approximately one-third of active UK science occupier demand originates from firms embedding artificial intelligence into R&D as global technology leaders actively expand their physical R&D footprints and deepen cross-sector collaborations. 

Outside the Golden Triangle, core location constraints are directing capital toward secondary hubs in Manchester, Edinburgh, Birmingham, Stevenage, Bristol, Liverpool, and Glasgow.

The UK registered its most active year on record for elderly care property transactions in 2025, with investment reaching GBP 10.25bn (EUR 11.8bn) - a 226% year-on-year increase accounting for nearly 75% of total European volume.

In H1 2026, UK elderly care investment normalised to GBP 790m (including GBP 500m in Q2), aligning with H1 2023 and H1 2024 performance. WholeCo (PropCo and OpCo) transactions represented 82.5% of H1 2026 activity, with US capital accounting for 38.6%. 

Market occupancy stood firm at 88.3% in Q1 2026 (86.0% for Grade A stock, 88.5% for Grade B, and 90.2% for Grade C). 

Average Weekly Fees reached GBP 1,440 - a 7.5% year-on-year increase - ranging from GBP 1,698 for Grade A assets to GBP 1,240 for Grade C stock. Operational profit margins averaged 30.1% overall and 37.4% for Grade A assets. 

Yields remained stable, with Prime PropCo yields at 4.75%, Prime SPV Tenant yields at 5.75%, and Secondary stock yields exceeding 8.00%. 

Demographics show a UK over-65 population of 13.4 million (19% of total, projected to reach 23% by 2040), while the over-80 cohort is set to grow from 3.7 million to 5.2 million. The market is led by major corporate care providers operating portfolios ranging between 6,700 and 18,000 beds nationwide.

London's luxury private hospital market, valued within a broader UK private hospital sector worth GBP 7.2bn, presents a defensive investment case supported by cross-border capital. Private medical travel to the UK grew by 800% over the past decade, with Middle Eastern visitors generating 59% of overseas patient demand. 

International health systems drive high occupancy across London's 74 private hospitals and Private Patient Units. Hospital shell and core rents in central London command up to GBP 130 per sq ft on long-term leases. 

Physical capacity bottlenecks across the public system-evidenced by total NHS England waiting lists reaching 7.3 million patients in May 2026 and diagnostic waitlists standing at 1.92 million in June 2026-continue to underpin private demand. 

Public funding initiatives include a GBP 20m government rollout of AI X-ray diagnostics across NHS trusts by 2029 and a GBP 10bn national investment in digital data and AI infrastructure.

► Germany

German healthcare real estate investment volume reached between EUR 1.38 billion and EUR 1.82 billion in the first half of 2026, representing a 48% to 71.2% year-on-year increase and standing 30% above the long-term first-half average. 

Second-quarter transaction volume accounted for EUR 309 million to EUR 592 million, more than tripling prior-year Q2 levels. 

Portfolio transactions dominated market activity, generating EUR 1.40 billion or 30.7% to 83.7% of total volume, anchored by major nationwide inpatient portfolio sales. Foreign cross-border buyers provided up to 86.7% of invested capital in BNP Paribas metrics, with US investors securing two major portfolios. 

Average deal sizes expanded 64.6% to EUR 62.1 million, with deals over EUR 100 million capturing 82.4% of total volume. Full-year healthcare transaction volume is projected to reach EUR 2.5 billion to EUR 3.0 billion.

Nursing homes and inpatient care facilities led sector investment performance, securing EUR 781 million to EUR 850 million in completed deal volume. 

Clinics and rehabilitation centres generated nearly EUR 720 million, capturing an above-average 45% market share, while outpatient healthcare properties (including medical care centres/MVZs and medical office buildings) recorded EUR 62 million in second-quarter transaction activity as institutional demand expanded. 

Assisted living transaction volume remained subdued at EUR 29 million to EUR 40 million due to product shortages and limited new construction, while rehabilitation clinics achieved above-average activity, driven by owner-occupiers and conversions.

Prime net initial yields expanded to 5.10% to 5.50% for care homes, 4.50% for senior/assisted living, 4.75% for outpatient facilities, and 5.75% for inpatient hospitals. 

Legislative reforms, including the Hospital Reform Adjustment Act (KHAG) passed in March 2026 and the EUR 50 billion Hospital Transformation Fund (KHTF), are accelerating an operational shift where up to 60% of inpatient cases transition to outpatient healthcare campuses.

In the life sciences real estate sector, investment volume reached approximately EUR 112 million across eight assets in the first half of 2026, matching full-year 2025 levels. 

Investor preference was overwhelmingly concentrated in high-quality core assets in established research micro-clusters, which accounted for 83% of total transaction volume. Primary micro-clusters include Munich-Martinsried, Heidelberg’s Neuenheimer Feld, Berlin-Adlershof, and Mainz. 

Office-to-laboratory conversions remain a specialist niche, with conversion costs ranging from EUR 250/sqm to over EUR 1,600/sqm due to strict floorplate geometry, floor loading, ventilation, power supply, and biological isolation requirements. 

Integrated facilities combining wet labs, office space, and high-performance computing are increasingly demanded as artificial intelligence shifts early-stage research toward digital simulation.

► France

France holds the fifth-largest pharmaceutical market value globally, with public and private healthcare expenditure accounting for 11.2% of GDP-the highest proportion in the EU, ahead of the Netherlands (9.9%) and the UK (9.8%). 

The country ranks second in Europe for pharmaceutical employment and fourth for medical technology employment. 

The state-led France 2030 industrial plan allocates EUR 7.5bn specifically through the Healthcare Innovation 2030 initiative to establish biotech clusters, streamline clinical trial frameworks, produce at least 20 biomedicines domestically, double biomanufacturing jobs to 20,000, and create five intermediate-sized enterprises. 

Research and development tax incentives are led by the Crédit d'Impôt Recherche, which provides a 30% tax credit on eligible R&D expenses up to EUR 100m.

The domestic ecosystem includes over 820 biotechs, with 25% focusing on oncology, 21% on rare diseases, and major hubs developing in cell and gene therapy as well as AI drug discovery. 

Collaboration across the sector is facilitated by six health competitiveness clusters. The Paris region generates 5.4% of EU GDP and hosts an ecosystem of over 1,000 life sciences companies (including 300 pharmaceutical, 200 biotech, and over 350 medtech firms), 45 hospitals, and 70,000 healthcare professionals. 

Corporate pharmaceutical headquarters strongly favour western inner suburbs such as La Défense, Rueil Malmaison, and Boulogne Billancourt. 

Because laboratory space requires lower occupational density (~19 sq m per employee compared to 11 sq m in traditional offices), laboratory occupiers predominantly target outer southern suburbs like Gentilly, where rents average 55% to 65% of La Défense rates. 

The Lyon region represents France's second life sciences hub, employing 80,000 people across healthcare, pharma, and medtech. Lyon hosts Hospices Civils de Lyon, France's only Biosafety Level 4 laboratory, the WHO IARC EUR 60m Nouveau Centre, and the WHO World Academy. 

Key submarkets include the Lyon-Gerland Biodistrict (employing 5,000 workers and housing the 2,000-sq-m Infectiology Center) and Bioparc Lyon (comprising multiple facilities including the 7,000-sq-m Quanta facility).

Healthcare real estate investment in France totalled EUR 670m in 2025, with nursing homes representing 34% (EUR 230m). Prime nursing home yields held stable at 5.00% in Paris and Greater Paris, 5.50% in provincial markets, 5.25% for follow-up care clinics, and 5.50% for short-stay clinics. 

France offers 615,000 beds across 7,500 nursing homes (45% public, 31% non-profit, 24% private), with required capacity projected to reach 720,000 beds by 2030 and 920,000 by 2045. 

Top private operators control portfolios ranging between 6,700 and 22,500 beds. Key transactions in 2025 included a 13-nursing-home sale-and-leaseback portfolio acquired for EUR 120m, alongside individual acquisitions of prime care homes and psychiatric clinics totalling EUR 120m. 

Mainstream commercial leases in France adhere strictly to a statutory 3/6/9-year framework with triennial break options, whereas life sciences occupiers sign commitments of significantly longer duration. 

Office-to-laboratory conversions require extensive technical evaluation covering floor loading, power capacity, structural geometry, and regulatory environmental permits. Property ESG strategies are governed by compliance with the Tertiary Decree, mandating HVAC energy efficiency, renewable energy procurement, and waste management protocols.

► Spain

Spain ranks among Europe's top 10 life sciences markets, nationally ranking fifth in total sector companies, seventh in venture capital funding (EUR 1.357bn raised), 11th in research quality, 12th in university attractiveness, and 12th in patent filings. 

The Spanish pharmaceutical sector generates over 20% of private industrial R&D expenditure and 25% of industrial research jobs, employing 49,000 people directly, with the country supporting over 4,000 biotechnology companies (50% healthcare-related) and more than 1,000 medical technology firms employing 29,000 people. 

Tax frameworks provide up to a 42% deduction for R&D expenditure, 12% for technological innovation, and a 40% social security deduction for R&D staff. 

Spanish laboratory rents offer a substantial cost advantage, averaging EUR 18 to EUR 30/sq m/month compared to US rates of up to EUR 70/sq m/month. Life sciences occupiers currently account for 4.6% of Spain's total office inventory across more than 50 science and technology parks.

Barcelona and Madrid lead the national sector, jointly hosting 1,700 companies, 72,700 professionals, and generating EUR 26.3bn in combined revenues, with Barcelona hosting 90 research institutions and over 1,300 companies alone. 

Madrid hosts 17% of Spain's biotech companies, anchored by major corporate presences, while secondary regional hubs are expanding across Málaga, Valencia, the Basque Country, and Seville.

Elderly care real estate investment in Spain dropped to EUR 103m in 2025 (down from EUR 220m in 2024) due to a lack of large portfolio transactions. Prime yields for modern care homes in top cities stood at 5.50%, with older secondary stock trading at 6.00% or higher. 

► Portugal

Portuguese commercial real estate investment reached EUR 2.67bn to EUR 2.70bn in 2025, representing a 10% to 11% year-on-year increase that surpassed the rolling three-year average by 13%. 

Investment momentum continued into H1 2026 with EUR 1.42bn in closed transactions (up 11% year-on-year), front-loaded by Q1 2026 (exceeding EUR 900m) before Q2 normalised at EUR 490m. 

Full-year 2026 investment is projected to reach EUR 2.40bn to EUR 2.70bn, supported by stable financing benchmarks, European Central Bank rate cuts, and a strengthening sovereign credit profile. 

Cross-border institutional capital accounted for 60% to 65% of investment outlays across 2025 and early 2026. 

Prime yields across commercial sectors remained firm, with Lisbon offices at 5.00%, Porto offices at 6.50%, logistics at 5.50%, high-street retail at 4.00%, shopping centres at 6.15%, and healthcare and senior housing yields holding at 5.50% to 5.75%. 

Private debt deployment across the Iberian peninsula is projected to expand to EUR 25bn-EUR 30bn by late 2026, funding operational real estate and forward purchases.

Sector expansion is driven by national public health service supply constraints, rapid demographic ageing, long public waitlists, and record private health insurance adoption. 

The population aged 80 and over reached 7.0% in 2024 (above the EU average of 6.1%) and is projected to reach 12.7% by 2050. Portugal operates approximately 2,610 nursing homes containing 107,600 beds, where non-profits dominate and private operators hold a 25% market share. Leading private operators control portfolios ranging from 615 to 1,167 beds. 

Prime Portuguese care home yields (5.50% to 5.75%) maintain a 50 to 75 basis point spread over mature core European markets. 

Acute care private hospitals command yields of 5.00% to 5.50% under inflation-indexed triple-net leases with weighted average unexpired lease terms of 20 to 30 years, while outpatient clinics trade at 5.25% to 5.75% and secondary care homes trade at 6.00% to 6.75%. 

Major portfolio transactions headlined activity in 2025 and 2026, including the July 2026 acquisition of three private hospitals in Lisbon, Porto, and Albufeira for an enterprise valuation of up to EUR 250m (encompassing 90,000 sq m, 353 beds, 21 operating theatres, and 267 consultation rooms), fully leased to top care providers. 

Portugal operates as a specialised European hub for contract development and manufacturing organisations, medical technology fabrication, active pharmaceutical ingredient synthesis, and digital health software engineering. 

The domestic pharmaceutical market was valued at EUR 3.8bn, while national health sector exports reached EUR 5.65bn across 186 destination markets in 2025. Portugal ranks fifth globally in health researcher density per million inhabitants and 10th in the EU Digital Health Indicators study. 

Primary life sciences clusters are established across the Oeiras Valley and Taguspark ecosystem in Greater Lisbon, Biocant Park in Cantanhede near Coimbra, and the Northern Industrial Corridor. 

► Italy

Italy ranks third in Europe for direct medical technology employment and fourth for pharmaceutical employment. The national sector generates an aggregate production value of EUR 90bn excluding healthcare services across roughly 5,000 companies and 150,000 employees.

Including healthcare delivery, total sector turnover reaches EUR 225bn, representing approximately 10% of Italian GDP. 

Italy represents Europe's largest functional foods market and ranks second globally behind the US in nutraceutical scientific output. In the commercial office sector, healthcare operators, diagnostic providers, and light medical services are increasingly absorbing vacant office space to establish urban outpatient clinics.

Lombardy represents the core national hub, accounting for 30% of Italy's life sciences revenues and 20% of sector employment, while Milan hosts approximately one-third of all clinical trials in Italy, supporting around 350,000 life sciences workers, 130,000 healthcare staff, 17 advanced research hospitals, and over 250 biotech firms. 

Sector locations across Milan are historically dispersed, driven primarily by highway accessibility. The flagship masterplan for the region is the Milano Innovation District (MIND), a 100-hectare mixed-use urban regeneration project on the former World Expo 2015 site with an estimated development end value of EUR 3.2bn across more than 1 million sq m. 

Healthcare real estate investment in Italy rebounded sharply to approximately EUR 600m in 2025, with nursing homes capturing 68% of total volume (EUR 408m). Prime healthcare yields held at 5.75%. 

Italian demographics indicate that citizens aged 65 and over represent 24.7% of the population, while the over-80 cohort accounts for almost 8%. Nursing home occupancy levels recovered to 92%-95% in 2025, underpinned by structural supply deficits in northern Italy.

► Central and Eastern Europe (CEE)

Poland represents CEE's largest pharmaceutical market and the sixth largest in the EU, supported by a national population of 40 million. Polish pharmaceutical sales reached USD 15.6bn (EUR 14.2bn) in 2021 and are forecasted to hit USD 23.8bn by 2026 and USD 33.3bn by 2031. 

Medical devices revenue is projected to reach USD 4.5bn by 2027. Sector expansion is guided by the Polish government's Development Plan for the Biomedical Sector (2022-2031), administered by the Medical Research Agency to provide research grants for domestic generic and biosimilar production. 

Warsaw serves as the primary regional clinical research and corporate headquarters hub, boasting a population of 1.9 million and nearly 255,000 university students, hosting major multinational pharmaceutical and clinical research firms. 

Krakow represents Poland's second life sciences centre, featuring 20 higher education institutions and a regional population of 8 million within 100 km. The city offers 1.7 million sq m of office space, with an additional 125,000 sq m under construction. 

The LifeScience Cluster Krakow, established in 2006, coordinates regional commercialisation across health and bioeconomy value chains. The flagship real estate asset is the Life Science Park, owned and managed by the Jagiellonian Center of Innovation, comprising 20,000 sq m across three buildings.

Key corporate presences in Krakow include multinational pharmaceutical R&D partnerships, preclinical contract research organisations with new laboratory headquarters, computational medicine institutes, and bio-pharmaceutical manufacturing entities.

► Pan-European Life Sciences and Healthcare Outlook

Looking ahead, European life sciences and healthcare real estate has cemented itself as a structural cornerstone of institutional portfolios. Propelled by irreversible demographic shifts and a relentless pace of scientific innovation, the asset class offers unique insulation from traditional economic cycles. 

The market is moving definitively beyond isolated buildings, favouring integrated, pan-European ecosystems where clinical care, advanced research, and commercialisation seamlessly converge.To capture premium returns in this maturing landscape, capital must pivot from passive ownership to deep operational partnerships. 

Future outperformance will rely on delivering highly adaptable infrastructure capable of evolving alongside rapid technological breakthroughs and shifting models of patient care. Ultimately, investors who successfully align physical real estate with these complex human and scientific needs will define the sector's next decade of growth.
 

► Check out our upcoming GRI Institute Europe gatherings to join the conversation

Sources:
BNP Paribas
CBRE
Colliers
CoStar
Cushman & Wakefield
Euronews
EY
JLL
KPMG
Life Sciences Real Estate
Savills